Prometic Life Sciences LTD

Human Genome Sciences is a biopharmaceutical company based in Rockville, MD. The company focuses on developing novel therapies and treatments for various diseases and medical conditions. With a commitment to advancing healthcare through innovative research and development, Human Genome Sciences aims to improve patient outcomes and quality of life through its cutting-edge scientific discoveries and pharmaceutical products. Generated from their business information

Hansoh Bio LLC, a leading innovation-driven pharmaceutical company based in Rockville, MD, is dedicated to enhancing human health through continuous innovation. With over 20 years of investment in research and development, the company has successfully marketed seven innovative drugs and maintains a robust pipeline of over 30 drug programs across various clinical stages. Focusing on critical therapeutic areas such as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, and autoimmune diseases, Hansoh Bio is committed to addressing unmet clinical needs. The company's diverse product portfolio includes advanced treatments for common and complex conditions, showcasing its dedication to improving healthcare outcomes globally. Generated from the website

GlycoMimetics develops novel small molecule therapeutics based upon the roles that carbohydrates play in biological processes. The company believes that carbohydrate mimics, or glycomimetic compounds, represent a new class of drugs. It has identified some compounds with potential therapeutic utility. One class has potential in the treatment of infectious diseases with a novel mechanism of action; the second is a class of anti-inflammatory compounds that have been shown to reduce key measures of inflammation. One of GMI s lead opportunities is to treat or prevent infections caused by Pseudomonas aeruginosa. Its objective in this program is to develop a drug that would be used in conjunction with antibiotics against chronic infections that have failed to respond to antibiotic treatment. The company also has compounds that inhibit selectin binding. Its initial focus in this program is to develop a product to treat acute exacerbations of asthma and chronic obstructive pulmonary disease. GlycoMimetics is headquartered in Gaithersburg, Md.